Get the Stockscreener App
5.115
0.78%
-0.045
Olema Pharmaceuticals Inc stock is traded at $5.115, with a volume of 237.64K.
It is down -0.78% in the last 24 hours and up +2.20% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$5.16
Open:
$5.08
24h Volume:
237.64K
Relative Volume:
0.27
Market Cap:
$349.97M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.3791
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
+8.70%
1M Performance:
+2.20%
6M Performance:
-41.69%
1Y Performance:
-41.35%
1-Day Range:
$4.98
$5.18
1-Week Range:
$4.51
$5.19
52-Week Range:
$2.86
$16.62
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
5.115 | 320.90M | 0 | -96.66M | -83.73M | -2.15 |
|
ONC
Beigene Ltd Adr
|
241.12 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.55 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.39 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.97 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - MSN
Olema Oncology Advances Cancer Trials with Strong Financials - TipRanks
Olema Oncology to Participate in Upcoming Investor Conferences | - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences | OLMA Stock News - GuruFocus
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Breast Cancer Biotech Olema Sets Major Presentations at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Paradigm Biocapital Advisors LP Purchases 1,801,370 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by MPM Bioimpact LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $153,000 Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
The Goldman Sachs Group Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $18.00 - Defense World
Oppenheimer Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $22.00 - Defense World
Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst - Defense World
Voya Investment Management LLC Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Driehaus Capital Management LLC Takes $1.28 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - Yahoo Finance
Olema Pharmaceuticals (OLMA) Price Target Lowered by Oppenheimer - GuruFocus
Balyasny Asset Management L.P. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals (OLMA) Price Target Lowered by Goldman Sachs | OLMA Stock News - GuruFocus
Olema Oncology (OLMA) Price Target Adjusted Amid Upcoming Data R - GuruFocus
Lightspeed Management Company L.L.C. Makes New Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology (OLMA) Pushes Forward with Promising Cancer Treat - GuruFocus
Olema Oncology (OLMA) Pushes Forward with Promising Cancer Treatments | OLMA Stock News - GuruFocus
Olema Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Olema Oncology Reports First Quarter 2025 Financial and Operating Results - The Manila Times
Olema Oncology Strengthens Breast Cancer Pipeline: Key Phase 3 Trial Updates and $392M War Chest - Stock Titan
Hsbc Holdings PLC Invests $58,000 in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday - MarketBeat
Deep Track Capital LP Decreases Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Dimensional Fund Advisors LP Cuts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Wells Fargo & Company MN Raises Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by BVF Inc. IL - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Barclays PLC - Defense World
Boxer Capital Management LLC Takes Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Market Insight: Olema Pharmaceuticals Inc (OLMA)’s Notable Drop, Closing at 4.60 - DWinneX
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Acquired by Renaissance Technologies LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):